Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Immuno-Biological Laboratories Co., Ltd.. A complete text table follows the diagram.
Immunity-related revenue supplied nearly all sales as overseas ELISA kits and antibody orders offset weaker testing volume.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Immunity Related | 1 | 484M | 99.7% of reported total |
| Cosmetics | 1 | 1.4M | 0.3% of reported total |
| Other & rounding | 1 | 0 | 0.0% of reported total |
| Revenues From External Customers | 2 | 485M | Reported six-month total · ¥485M |
| Operating profit | 3 | 142M | 29.3% operating margin |
| Operating costs & expenses | 3 | 343M | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 150M | Reported pretax result |
| Antibody kits and outsourced science carry a leaner biotech platform | 3 | 7.7M | Overseas ELISA and antibody demand expanded while testing volumes and cosmetics sales weakened; center consolidation restored operating leverage. |
| Net profit attributable to owners | 5 | 142M | Reported parent-company result |
| Tax, attribution & other | 5 | 8.2M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Immunity Related | Revenues From External Customers | 484M |
| Cosmetics | Revenues From External Customers | 1.4M |
| Other & rounding | Revenues From External Customers | 0 |
| Revenues From External Customers | Operating profit | 142M |
| Revenues From External Customers | Operating costs & expenses | 343M |
| Operating profit | Profit before tax | 142M |
| Antibody kits and outsourced science carry a leaner biotech platform | Profit before tax | 7.7M |
| Profit before tax | Net profit attributable to owners | 142M |
| Profit before tax | Tax, attribution & other | 8.2M |